Table 2 HPV vaccine efficacy against genital disease in FUTURE I/II (Gardasil®) and PATRICIA (Cervarix®) trials
From: Answering human papillomavirus vaccine concerns; a matter of science and time
HPV 16/18 associated | % efficacy (95% CI) | Rate reduction |
|---|---|---|
FutureI/II | Â | |
MITT/TVC-naive | Â | Â |
CIN2 | 100.0 (91.9-100) | 0.3 |
CIN3 | 100.0 (90.5-100) | 0.2 |
AIS | 100.0 (<0-100) | <0.1 |
VIN2/3 or VAIN2/3 | 95.4 (71.5-99.9) | <0.1 |
Genital warts | 96.4 (91.4-98.9) | 0.8 |
ITT/TVC | Â | Â |
CIN2 | 54.8 (40.8-65.7) | 0.3 |
CIN3 | 45.1 (29.8-57.3) | 0.3 |
AIS | 60.0 (<0-87.3) | <0.1 |
VIN2/3 or VAIN2/3 | 78.5 (55.2-90.8) | <0.1 |
Genital warts | 79.5 (73.0-84.6) | 0.8 |
PATRICIA | Â | Â |
MITT/TVC-naive | Â | Â |
CIN2+ | 99.0 (94.2-100) | 0.47 |
CIN3+ | 100.0 (85.5-100) | 0.13 |
AIS | 100.0 (15.5-100) | 0.03 |
ITT/TVC | Â | Â |
CIN2 | 60.7 (49.6-69.5) | 0.43 |
CIN3 | 45.7 (22.9-62.2) | 0.13 |
AIS | 70.0 (–16.6-94.7) | 0.02 |